The authors have looked to answer an important question around the medical management of adenoid hypertrophy, with appropriately reported results and drawn conclusions.
The only additional comment I would add is that the authors have not reported the incidence of neuropsychiatric side effects, which have been the main driver for avoiding leukotriene antagonists like montelukast in regular practice. Would improve the quality of the article if the authors could report/comment on the same.

Dear authors,
Thank you for clarifying the reason for not addressing the neuropsychiatric side effect profile of montelukast. It would be great if this could be included in a short sentence in the limitations or in the scope for future research, as it is an important factor when weighing risks/benefit of an intervention.